Bile acid sequestrants and diabetes: introduction and overview to the supplement.
Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.
Jialal
I
I
Laboratory for Atherosclerosis and Metabolic Research, University of California Davis Medical Center, Sacramento, California, USA.
D000499:Allylamine / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D000924:Anticholesteremic Agents / Q000378:metabolism* / Q000627:therapeutic use*; D001647:Bile Acids and Salts / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D000069472:Colesevelam Hydrochloride; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis / Q000187:drug effects; D006801:Humans
D000499:Allylamine; D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D008078:Cholesterol, LDL; D000069472:Colesevelam Hydrochloride; D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human